DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced that all resolutions
recommended by the Board at the Annual General Meeting of the Company
held on 19 July 2012 were duly passed by shareholders. These resolutions
were set out in the Notice of the Annual General Meeting sent to
shareholders on 12 June 2012 and are available on the ICON plc website www.iconplc.com.
DISCLOSURE NOTICE: The information contained in this release is
as of July 20th, 2012. ICON assumes no obligation to update
forward-looking statements contained in this release. A description of
risks and uncertainties relating to ICON and its business can be found
in ICON's Annual Report and Form 20-F for the fiscal year ended December
31, 2011 and in its Reports of Foreign Issuer on Form 6-K filed with the
US Securities and Exchange Commission.
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has approximately 8,930
employees, operating from 83 locations in 40 countries.
Further information is available at www.iconplc.com
Source: ICON plc
ICON/ICLR-F
Contact:
Investor Relations
1-888-381-7923
or
Brendan
Brennan
Chief Financial Officer
+ 353 —1-291-2000
or
Sam
Farthing
VP Investor Relations
+ 353 —1-291-2000
All at
ICON.
Source: ICON
News Provided by Acquire Media
